More Combinations like Nivolumab and Ipilimumab Coming for Lung, Bladder, and Kidney Cancer
Lawrence Fong, MD of University of California, San Francisco discusses the use of more combinations therapies, like Nivolumab and Ipilimumab. This combination therapy is FDA approved for Melanoma, but...
Author: ASCO-SITC2017
Added: 03/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2017 Category: Cancer & Oncology Source Type: podcasts
Use of Biomarkers for Radiation Treatment of Invasive Bladder Cancer
Robert B. Den, MD of Sidney Kimmel Medical College at Thomas Jefferson University discusses how radiation has changed for invasive bladder cancer treatment. He explains the new and exciting research o...
Author: obr
Added: 03/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 3, 2017 Category: Cancer & Oncology Source Type: podcasts
How Genomics are Changing Treatment for Bladder Cancer Subtypes
Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are changing the way bladder cancer subtypes are being treated at the 2017 Genitourinary Cancers Symp...
Author: obr
Added: 02/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Use of Genomics in Understanding Heterogeneity in Bladder Cancer
Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are helping us understand heterogeneity in bladder cancer at the 2017 Genitourinary Cancers Symposium...
Author: obr
Added: 02/24/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2017 Category: Cancer & Oncology Source Type: podcasts
Are there any specific drugs that have potential to make an impact in Bladder Cancer
David J. McConkey, PhD of Johns Hopkins Greenberg Bladder Cancer Institute gives his take on what specific drugs have potential in treating bladder cancer at the 2017 Genitourinary Cancers Symposium (...
Author: obr
Added: 02/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Progress with Checkpoint Inhibitors in Treating Bladder Cancer
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute gives his opinion on what physicians need to know about the progress being made in treating bladder cancer with checkpoint i...
Author: obr
Added: 02/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Non-Invasive Imaging: What Methods to Use for Metastatic Bladder Cancer
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses whether or not non-invasive imaging will be ready in the future, and what methods should oncologists use to stage ...
Author: obr
Added: 02/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Why Do Some Bladder Cancer Subtypes Respond to Immunotherapy and Others Do Not
David J. McConkey of Johns Hopkins Greensberg Bladder Cancer Institute explains why some bladder cancer subtypes respond to immunotherapy and others do not at the 2017 Genitourinary Cancers Symposium ...
Author: obr
Added: 02/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2017 Category: Cancer & Oncology Source Type: podcasts
How are Genomics Changing the Way Bladder Cancer Subtypes are Being Treated
David J. McConkey, PhD of Johns Hopkins Greensberg Bladder Cancer Institute discusses genomics and how they change treatment for bladder cancer subtypes at the 2017 Genitourinary Cancers Symposium (AS...
Author: obr
Added: 02/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2017 Category: Cancer & Oncology Source Type: podcasts
How Do Genomics Help Understand Heterogeneity in Bladder Cancer
David J. McConkey, PhD of Johns Hopkins Greenberg Bladder Cancer Institute discusses how genomics help our understanding of heterogeneity in bladder cancer at the 2017 Genitourinary Cancers Symposium ...
Author: obr
Added: 02/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2017 Category: Cancer & Oncology Source Type: podcasts
ASCO GU 2017: Highlights in Bladder Cancer
Alexandra Drakaki, MD, PhD of University of California, Los Angeles gives an overview of the highlights in Bladder Cancer research that was presented at the 2017 Genitourinary Cancers Symposium (ASCO ...
Author: obr
Added: 02/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 21, 2017 Category: Cancer & Oncology Source Type: podcasts
What Physicians Need to Know about the Use of Checkpoint Inhibitors for Bladder Cancer Treatment
Alexandra Drakaki, MD, PhD of University of California, Los Angeles discusses what physicians need to know about the progress that's being made with checkpoint inhibitors for treatment of Bladder Canc...
Author: obr
Added: 02/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 21, 2017 Category: Cancer & Oncology Source Type: podcasts
Role of microRNA in Bladder Cancer
Alexandra Drakaki, MD, PhD of University of California, Los Angeles discusses the role of microRNA in Bladder Cancer and its clinical implications at the 2017 Genitourinary Cancers Symposium (ASCO GU)...
Author: obr
Added: 02/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 21, 2017 Category: Cancer & Oncology Source Type: podcasts
FDA Drug Safety Podcast: Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer
On December 12, 2016, FDA announced as a result of an updated review, that it has concluded that use of the type 2 diabetes medicine pioglitazone (brand names Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - December 28, 2016 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Trial of durvalumab for bladder cancer
Thomas Powles, MD, PhD from Barts Cancer Institute, London, UK discusses key points of a new Phase III clinical trial looking at moving immune single agent and immune combination therapy into the fron...
Author: VJOncology
Added: 08/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 18, 2016 Category: Cancer & Oncology Source Type: podcasts
